Antibody–drug conjugates (ADCs) constitute a relatively new group of anticancer agents,
whose first appearance took place about two decades ago, but a renewed interest occurred …

Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal
antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since …

Polatuzumab vedotin (pola) is a CD79b‐targeted antibody‐drug conjugate delivering a
potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open‐label, single …

Polatuzumab vedotin (PV) is an antibody-drug conjugate that has shown promising results
in the treatment of diffuse B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma …

Abstract Model‐informed drug development (MIDD) has become an important approach to
improving clinical trial efficiency, optimizing drug dosing, and proposing drug labeling in the …

Polatuzumab vedotin, marketed under the trade name POLIVY®, is a CD79b-targeted
antibody-drug conjugate that preferentially delivers a potent anti-mitotic agent (monomethyl …

Aims This study aims to develop a generalized pharmacokinetic (PK) model for monomethyl
auristatin E (MMAE)‐based antibody–drug conjugates (ADCs) that can simultaneously …

Purpose The established two-analyte integrated population pharmacokinetic model was
applied to assess the impact of intrinsic/extrinsic factors on the pharmacokinetics (PK) of …

Refractory/relapsed diffuse large B-cell lymphoma remains a major unmet medical need
with poor outcome, especially for patients considered ineligible for stem cell transplant …

Progress in the development and clinical efficacy of antibody‐drug conjugates (ADCs) has
attracted the interests of both academic researchers and the industry. The rationale for …